Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR positive, Wild type KRAS status confers therapeutic sensitivity to Cetuximab, Irinotecan in patients with Colorectal Adenocarcinoma.
This statement is based on a regulatory approval from the Health Canada:
ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.